Physician profile
Amity Bates
NPI 1154780591
$2,208.76
in general payments reported to CMS, 2019-2025
26 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,086 · 2023: $288 · 2024: $404 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.24 | 2021-2025 | |
| Pfizer INC. | $406.97 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $297.16 | 2021-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $136.66 | 2024-2025 | Wegovy |
| Janssen Biotech, INC. | $136.04 | 2021 | |
| Dermavant Sciences, INC. | $59.23 | 2024 | Vtama |
| Merck Sharp & Dohme LLC | $59.21 | 2023-2024 | Gardasil, Gardasil 9, Capvaxive |
| Aimmune Therapeutics, INC. | $57.79 | 2024-2025 | Zenpep |
| Celgene Corporation | $55.19 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $52.75 | 2024 | Zepbound, Jardiance, Mounjaro |
| Phathom Pharmaceuticals, INC. | $52.43 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $50.82 | 2021 | |
| Inari Medical, INC. | $27.23 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Axsome Therapeutics, INC. | $23.16 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $18.17 | 2025 | Trelegy Ellipta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $17.97 | 2024 | Fluad, Flucelvax |
| Actelion Pharmaceuticals US, INC. | $17.80 | 2024 | Uptravi, Opsumit |
| Boston Scientific Corporation | $17.23 | 2025 | General - Pain Management |
| Amgen INC. | $16.51 | 2023 | Repatha, Otezla |
| Ardelyx, INC. | $15.96 | 2023 | Ibsrela |
| Exact Sciences Corporation | $15.87 | 2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $15.15 | 2025 | Yupelri |
| Gilead Sciences, INC. | $14.81 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.45 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $13.95 | 2023 | |
| Abbott Laboratories | $13.01 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amity Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.